Safety Information

TOFIDENCE: demonstrated a comparable safety profile to Actemra1-4

Safety information from the TOFIDENCE Prescribing Information1

Studies were conducted with the reference product, Actemra

WARNING: RISK OF SERIOUS INFECTIONS

See full Prescribing Information for complete Boxed Warning.

  • Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving tocilizumab products.
  • If a serious infection develops, interrupt TOFIDENCE until the infection is controlled. 
  • Perform test for latent TB; if positive, start treatment for TB prior to starting TOFIDENCE.
  • Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

Ongoing monitoring of your patients is important during treatment with TOFIDENCE. Please see Safety and Lab Monitoring Guide or full Prescribing Information.

Safety Data from the TOFIDENCE Clinical Trial Program

Phase I Clinical Study in Healthy Volunteers

The PK parameters were comparable between groups2*

Parameter TOFIDENCE
(N=45)		 EU-Actemra (N=42) US-Actemra
(N=42)		 P-value GMR (90% CI)‡ GMR (90% CI)§ GMR (90% CI)‖
AUC0-∞ (μg*h/mL) 10,840 (16.6) 11,080 (19.5) 10,690 (15.4) 0.73 98.06
(92.10–104.41)		 100.82
(95.76–106.15)		 97.26
(91.75–103.10)
AUC0-t (μg*h/mL) 10,260 (17.8) 10,580 (21.5) 10,390 (16.4) 0.78 97.39
(91.01–104.20)		 98.18
(92.89–103.78)		 99.19
(93.22–105.53)
Cmax (μg/mL) 88.28 (14.5) 96.28 (17.6) 91.29 (16.4) 0.03 91.71
(86.90–96.79)		 96.25
(91.70–101.03)		 95.28
(90.04–100.82)
Tmax (h) 2.0 (1.0–9.0) 3.0 (1.0–5.0) 4 (0.98–9.02) NA - - -
t1/2 (h) 89.81 (32.4) 82.08 (33.5) 72.57 (30.7) NA - - -
CL (L/h) 0.02457 (16.4) 0.02421 (18.8) 0.02482 (13.0) NA - - -
Vz (L) 3.184 (32.9) 2.867 (32.6) 2.599 (32.4) NA - - -
AUCextrapolation
(%)		 5.35 (18.2) 4.51 (35.4) 2.80 (30.0) NA - - -

*Median [min, max]
†Bioequivalence by ANOVA if the 90% CIs for the ratio of geometric LS-means of the treatments compared were completely contained within the pre-defined equivalence margin, 0.8–1.25
‡TOFIDENCE/EU-Actemra
§TOFIDENCE/US-Actemra
‖US-Actemra

ANOVA=analysis of variance; AUC0-t=area under the curve from zero to the final quantifiable concentration; AUC0–∞=area under the curve from zero to infinity; CL=clearance; Cmax=maximum observable serum concentration; GMR=geometric mean ratio; Tmax=the concentration-time data included time to peak; t1/2=half-life, Vz=volume of distribution.

Safety data from the Phase I clinical study2

Number (%) of subjects
TOFIDENCE
(n=45) 		EU-Actemra
(n=42) 		US-Actemra
(n=42) 		Overall
(N=129) 		P*
Number of participants with treatment-related TEAEs 27 (60.0) 34 (81.0) 32 (76.2) 93 (72.1) 0.07
Investigations 21 (46.7) 26 (61.9) 27 (64.3) 74 (57.4) 0.19
Neutrophil count decreased 12 (26.7) 20 (47.6) 25 (59.5) 57 (44.2) 0.007
White blood cell count decreased 7 (15.6) 12 (28.6) 16 (38.1) 35 (27.1) 0.06
Alanine aminotransferase increased 6 (13.3) 10 (23.8) 7 (16.7) 23 (17.8) 0.43
Aspartate aminotransferase increased 7 (15.6) 8 (19.0) 3 (7.1) 18 (14.0) 0.26
Blood bilirubin increased 0 (0.0) 5 (11.9) 4 (9.5) 9 (7.0) 0.07
Metabolism and nutrition disorders 11 (24.4) 15 (35.7) 8 (19.0) 34 (26.4) 0.20
Hypertriglyceridemia 9 (20.0) 11 (26.2) 6 (14.3) 26 (20.2) 0.39
Hyperuricemia 3 (6.7) 4 (9.5) 4 (9.5) 11 (8.5) 0.85
Blood and lymphatic system disorders 2 (4.4) 3 (7.1) 0 (0.0) 5 (3.9) 0.23
Cardiac disorders 0 (0.0) 4 (9.5) 1 (2.4) 5 (3.9) 0.06
Infections and infestations 1 (2.2) 3 (7.1) 1 (2.4) 5 (3.9) 0.40


Summary of common treatment-related emergent adverse events: P*, the number (%) of subjects with common treatment-related emergent adverse events were compared among the three groups.

Summary of immunogenicity assessment2
(number [%] of subjects with positive antibodies)

Parameter Time
(day)		 TOFIDENCE
(n=45)		 EU-Actemra
(n=42)		 US-Actemra
(n=42)		 Overall
(N=129)		 P*
ADA 0 2 (4) 0 0 2 (2) 0.15
15 3 (7) 3 (7) 3 (7) 9 (7) 0.99
43 11 (24) 9 (21) 9 (21) 9 (23) 0.92
57 19 (42) 10 (24) 12 (29) 41 (31) 0.15
NAb 0 1 (2) 0 0 1 (<1) 0.39
15 3 (7) 3 (7) 3 (7) 9 (7) 0.99
43 10 (22) 6 (14) 9 (19) 24 (19) 0.63
57 14 (31) 9 (21) 12 (29) 35 (27) 0.57


ADA=anti-drug antibody; NAb=neutralizing antibody; p*=the positive rates of ADA and NAb were compared among the three groups.


Phase III Clinical Study

Safety data from the TOFIDENCE clinical trial program3,4

Treatment period 13 Treatment period 24
N (%) TOFIDENCE
(n=312) n (%) 		Actemra
(n=309) n (%) 		TOFIDENCE
(n=290) n (%) 		Actemra/
TOFIDENCE
(n=142) n (%) 		Actemra
(n=145) n (%)
TEAE 201 (64) 196 (63) 162 (56) 92 (65) 90 (62)
Treatment-related TEAE 148 (47) 151 (49) 112 (39) 64 (45) 59 (41)
Serious TEAE 11 (4) 13 (4) 8 (3) 5 (4) 4 (3)
Treatment-related serious TEAE 2 (1) 7 (2) 2 (<1) 1 (<1) 1 (<1)
Fatal TEAE 3 (1) 1 (<1) 0 0 0
ADA-positive 64 (21) 42 (14) 61 (21) 23 (16) 27 (19)
NAb-positive 64 (21) 42 (14) 61 (21) 23 (16) 26 (18)

Safety set included all randomly assigned patients that had received study drug in treatment period 1 or treatment period 2 respectively.

Treatment Period 1

  • 7 subjects in the Actemra group reported 12 related serious TEAEs, 4 probably treatment-related and 8 possibly treatment-related
  • 2 subject in the TOFIDENCE group reported related serious TEAEs, 1 probably treatment-related and 1 possibly treatment-related (ovarian carcinoma - fatal)
  • 4 subjects experienced a fatal TEAE
    - 1 in the Actemra group (unlikely related)
    - 3 in the TOFIDENCE group (2 unrelated, 1 possibly related)

Treatment Period 2

  • 4 subjects in the Actemra group reported 5 serious TEAEs, 1 possibly treatment-related
  • 8 subjects in the TOFIDENCE group reported 9 serious TEAEs, 2 possibly treatment-related
  • 5 subjects in the TOFIDENCE group reported serious TEAEs, 1 possibly treatment-related

Common TEAEs by preferred term in Treatment Period 13

Nonserious TEAEs with an occurrence below 5% are not reported here.

Total reports of any adverse event were comparable between
TOFIDENCE 66% (n=206) and Actemra 65% (n=201)3

The occurrence of all TEAEs was 64% (n=201) for TOFIDENCE and 63% (n=196) for Actemra3

Common treatment-related TEAEs by preferred term in Treatment Period 13

*All events occurred in <0.5% of patients.

Help start a movement for more patients

You also might be interested in:

 

ALT=alanine aminotransferase; AR=adverse reaction; DMARD=disease-modifying anti-rheumatic drug; NAb=neutralizing antibody; TEAE=treatment-emergent adverse event.

 

References
  1. TOFIDENCE Prescribing Information, Cambridge, MA: Biogen.
  2. Zhang H, Wang H, Wei H, et al. A phase l clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy Chinese men. Front Pharmacol. 2021;11:609522.
  3. Leng X, Leszczynski P, Jeka S, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. 2024;6(1):e40-e50.
  4. Leng X, Leszczynski P, Jeka S, et al. Fifty-Two-Week Results From a Phase 3, Randomized, Double-Blind, Active- Controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, With a Tocilizumab Reference Product in Subjects With Moderate to Severe RA With an Inadequate Response to Methotrexate. Poster P0917. Presented at the American College of Rheumatology (ACR). 10-14 November 2022, Philadelphia, PA, USA.
Click HERE to assist in determining the number and size of TOFIDENCE vials needed with the help of our dosing calculator

INDICATIONS

Rheumatoid Arthritis (RA)

TOFIDENCE™ (tocilizumab-bavi) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Polyarticular Juvenile Idiopathic Arthritis (PJIA)

TOFIDENCE is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

Systemic Juvenile Idiopathic Arthritis (SJIA)

TOFIDENCE is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
 

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS INFECTIONS

Patients treated with tocilizumab products including TOFIDENCE are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate (MTX) or corticosteroids.

If a serious infection develops, interrupt TOFIDENCE until the infection is controlled.

Reported infections include:

  • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before TOFIDENCE use and during therapy. Treatment for latent infection should be initiated prior to TOFIDENCE use.
  • Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with TOFIDENCE should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with TOFIDENCE, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.


CONTRAINDICATIONS

TOFIDENCE is contraindicated in patients with known hypersensitivity to tocilizumab products.


WARNINGS AND PRECAUTIONS

Serious Infections

Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, protozoal, or other opportunistic pathogens have been reported in patients receiving immunosuppressive agents including tocilizumab products. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. Among opportunistic infections, tuberculosis, cryptococcus, aspergillosis, candidiasis, and pneumocystosis were reported with tocilizumab products. Other serious infections, not reported in clinical studies, may also occur (e.g., histoplasmosis, coccidioidomycosis, listeriosis). Patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids which in addition to rheumatoid arthritis may predispose them to infections.

Do not administer TOFIDENCE in patients with an active infection, including localized infections. The risks and benefits of treatment should be considered prior to initiating TOFIDENCE in patients:

  • with chronic or recurrent infection;
  • who have been exposed to tuberculosis;
  • with a history of serious or an opportunistic infection;
  • who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
  • with underlying conditions that may predispose them to infection

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with TOFIDENCE, as signs and symptoms of acute inflammation may be lessened due to suppression of the acute phase reactants.

Hold TOFIDENCE if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with TOFIDENCE should undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, initiate appropriate antimicrobial therapy, and closely monitor the patient.

Tuberculosis

Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating TOFIDENCE.

Consider anti-tuberculosis therapy prior to initiation of TOFIDENCE in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Closely monitor patients for the development of signs and symptoms of tuberculosis including patients who tested negative for latent tuberculosis infection prior to initiating therapy.

The incidence of tuberculosis in worldwide clinical development programs is 0.1%. Patients with latent tuberculosis should be treated with standard antimycobacterial therapy before initiating TOFIDENCE.

Viral Reactivation

Viral reactivation has been reported with immunosuppressive biologic therapies and cases of herpes zoster exacerbation were observed in clinical studies with tocilizumab. No cases of Hepatitis B reactivation were observed in the trials; however patients who screened positive for hepatitis were excluded.

Gastrointestinal Perforations

Events of gastrointestinal perforation have been reported in clinical trials, primarily as complications of diverticulitis in patients treated with tocilizumab. Use TOFIDENCE with caution in patients who may be at increased risk for gastrointestinal perforation. Promptly evaluate patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.

Hepatotoxicity

Serious cases of hepatic injury have been observed in patients taking intravenous tocilizumab products. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation with tocilizumab products. While most cases presented with marked elevations of transaminases (> 5 times upper limit of normal [ULN]), some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.

During randomized controlled studies, treatment with tocilizumab was associated with a higher incidence of transaminase elevations. Increased frequency and magnitude of these elevations was observed when potentially hepatotoxic drugs (e.g., MTX) were used in combination with tocilizumab.

For RA patients, obtain a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) before initiating TOFIDENCE, every 4 to 8 weeks after start of therapy for the first 6 months of treatment and every 3 months thereafter. It is not recommended to initiate TOFIDENCE treatment in RA patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN, discontinue TOFIDENCE.

Measure liver tests promptly in patients who report symptoms that may indicate liver injury, such as fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have abnormal liver tests (e.g., ALT greater than three times the upper limit of the reference range, serum total bilirubin greater than two times the upper limit of the reference range), TOFIDENCE treatment should be interrupted and investigation done to establish the probable cause. TOFIDENCE should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.

A similar pattern of liver enzyme elevation is noted with tocilizumab products treatment in the PJIA and SJIA populations. Monitor liver test panel at the time of the second administration and thereafter every 4 to 8 weeks for PJIA and every 2 to 4 weeks for SJIA.

Changes in Laboratory Parameters

Patients with Rheumatoid Arthritis

Neutropenia

Treatment with tocilizumab products was associated with a higher incidence of neutropenia. Infections have been uncommonly reported in association with treatment-related neutropenia in long-term extension studies and postmarketing clinical experience.

It is not recommended to initiate TOFIDENCE treatment in RA patients with a low neutrophil count, i.e., absolute neutrophil count (ANC) less than 2000 per mm3. In patients who develop an absolute neutrophil count less than 500 per mm3 treatment is not recommended.

Monitor neutrophils 4 to 8 weeks after start of therapy and every 3 months thereafter.

Thrombocytopenia

Treatment with tocilizumab products was associated with a reduction in platelet counts. Treatment-related reduction in platelets was not associated with serious bleeding events in clinical trials.

It is not recommended to initiate TOFIDENCE treatment in RA patients with a platelet count below 100,000 per mm3. In patients who develop a platelet count less than 50,000 per mm3 treatment is not recommended.

Monitor platelets 4 to 8 weeks after start of therapy and every 3 months thereafter.

Elevated Liver Enzymes

Refer to Hepatotoxicity. (See above.)

Lipid Abnormalities

Treatment with tocilizumab products was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterol, and/or HDL cholesterol.

Assess lipid parameters approximately 4 to 8 weeks following initiation of TOFIDENCE therapy.

Subsequently, manage patients according to clinical guidelines [e.g., National Cholesterol Educational Program (NCEP)] for the management of hyperlipidemia.

Patients with Polyarticular and Systemic Juvenile Idiopathic Arthritis

A similar pattern of liver enzyme elevation, low neutrophil count, low platelet count and lipid elevations is noted with tocilizumab products treatment in the PJIA and SJIA populations. Monitor neutrophils, platelets, ALT and AST at the time of the second administration and thereafter every 4 to 8 weeks for PJIA and every 2 to 4 weeks for SJIA. Monitor lipids as above for approved adult indications.

Immunosuppression

The impact of treatment with tocilizumab products on the development of malignancies is not known but malignancies were observed in clinical studies. TOFIDENCE is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.

Hypersensitivity Reactions, Including Anaphylaxis

Hypersensitivity reactions, including anaphylaxis, have been reported in association with tocilizumab products and anaphylactic events with a fatal outcome have been reported with intravenous infusion of tocilizumab products. Anaphylaxis and other hypersensitivity reactions that required treatment discontinuation were reported in 0.1% (3 out of 2644) of patients in the 6-month controlled trials of intravenous tocilizumab and 0.2% (8 out of 4009) of patients in the intravenous all-exposure RA population. In the SJIA controlled trial with intravenous tocilizumab, 1 out of 112 patients (0.9%) experienced hypersensitivity reactions that required treatment discontinuation. In the PJIA controlled trial with intravenous tocilizumab 0 out of 188 patients (0%) in the tocilizumab all-exposure population experienced hypersensitivity reactions that required treatment discontinuation. Reactions that required treatment discontinuation included generalized erythema, rash, and urticaria. Injection site reactions were categorized separately.

In the postmarketing setting, events of hypersensitivity reactions, including anaphylaxis and death, have occurred in patients treated with a range of doses of intravenous tocilizumab products, with or without concomitant therapies. Events have occurred in patients who received premedication. Hypersensitivity, including anaphylaxis events, have occurred both with and without previous hypersensitivity reactions and as early as the first infusion of tocilizumab products. TOFIDENCE for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of TOFIDENCE immediately and discontinue TOFIDENCE permanently. Do not administer TOFIDENCE to patients with known hypersensitivity to tocilizumab products.

Demyelinating Disorders

The impact of treatment with tocilizumab products on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in RA clinical studies. Monitor patients for signs and symptoms potentially indicative of demyelinating disorders. Prescribers should exercise caution in considering the use of TOFIDENCE in patients with preexisting or recent onset demyelinating disorders.

Active Hepatic Disease and Hepatic Impairment

Treatment with TOFIDENCE is not recommended in patients with active hepatic disease or hepatic impairment.

Vaccinations

Avoid use of live vaccines concurrently with TOFIDENCE as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving tocilizumab products.

No data are available on the effectiveness of vaccination in patients receiving tocilizumab products. Because IL-6 inhibition may interfere with the normal immune response to new antigens, it is recommended that all patients, particularly pediatric or elderly patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating TOFIDENCE therapy. The interval between live vaccinations and initiation of TOFIDENCE therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.


ADVERSE REACTIONS

Rheumatoid Arthritis

The tocilizumab-IV data in rheumatoid arthritis includes 5 double-blind, controlled multicenter studies. In these studies, patients received doses of tocilizumab-IV 8 mg per kg monotherapy (288 patients), tocilizumab-IV 8 mg per kg in combination with DMARDs (including methotrexate) (1582 patients), or tocilizumab-IV 4 mg per kg in combination with methotrexate (774 patients).

The all exposure population includes all patients in registration studies who received at least one dose of tocilizumab-IV. Of the 4009 patients in this population, 3577 received treatment for at least 6 months, 3309 for at least one year; 2954 received treatment for at least 2 years and 2189 for 3 years.

The most commonly reported adverse reactions in controlled studies up to 24 weeks (occurring in at least 5% of patients treated with tocilizumab-IV monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.

Serious Infections

In the 24 week, controlled clinical studies, the rate of serious infections in the tocilizumab-IV monotherapy group was 3.6 per 100 patient-years compared to 1.5 per 100 patient-years in the methotrexate group. The rate of serious infections in the 4 mg per kg and 8 mg per kg tocilizumab-IV plus DMARD group was 4.4 and 5.3 events per 100 patient-years, respectively, compared to 3.9 events per 100 patient-years in the placebo plus DMARD group.

In the all-exposure population, the overall rate of serious infections remained consistent with rates in the controlled periods of the studies. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. Cases of opportunistic infections have been reported.

Infusion Reactions

In the 24 week, controlled clinical studies, adverse events associated with the infusion (occurring during or within 24 hours of the start of infusion) were reported in 8% and 7% of patients in the 4 mg per kg and 8 mg per kg tocilizumab-IV plus DMARD group, respectively, compared to 5% of patients in the placebo plus DMARD group. The most frequently reported event on the 4 mg per kg and 8 mg per kg dose during the infusion was hypertension (1% for both doses), while the most frequently reported event occurring within 24 hours of finishing an infusion were headache (1% for both doses) and skin reactions (1% for both doses), including rash, pruritus and urticaria. These events were not treatment limiting.

Anaphylaxis

Hypersensitivity reactions requiring treatment discontinuation, including anaphylaxis, associated with tocilizumab-IV were reported in 0.1% (3 out of 2644) in the 24 week, controlled trials and in 0.2% (8 out of 4009) in the all-exposure population. These reactions were generally observed during the second to fourth infusion of tocilizumab-IV. Appropriate medical treatment should be available for immediate use in the event of a serious hypersensitivity reaction.

Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. In the 24 week, controlled clinical studies, a total of 2876 patients have been tested for anti-tocilizumab antibodies. Forty-six patients (2%) developed positive anti-tocilizumab antibodies, of whom 5 had an associated, medically significant, hypersensitivity reaction leading to withdrawal. Thirty patients (1%) developed neutralizing antibodies.

Polyarticular Juvenile Idiopathic Arthritis

The safety of tocilizumab-IV was studied in 188 pediatric patients 2 to 17 years of age with PJIA who had an inadequate clinical response or were intolerant to methotrexate. The total patient exposure in the tocilizumab-IV all exposure population (defined as patients who received at least one dose of tocilizumab-IV) was 184.4 patient years. At baseline, approximately half of the patients were taking oral corticosteroids and almost 80% were taking methotrexate. In general, the types of adverse drug reactions in patients with PJIA were consistent with those seen in RA and SJIA patients.

Infections

The rate of infections in the tocilizumab-IV all exposure population was 163.7 per 100 patient years. The most common events observed were nasopharyngitis and upper respiratory tract infections. The rate of serious infections was numerically higher in patients weighing less than 30 kg treated with 10 mg/kg tocilizumab (12.2 per 100 patient years) compared to patients weighing at or above 30 kg, treated with 8 mg/kg tocilizumab (4.0 per 100 patient years). The incidence of infections leading to dose interruptions was also numerically higher in patients weighing less than 30 kg treated with 10 mg/kg tocilizumab (21%) compared to patients weighing at or above 30 kg, treated with 8 mg/kg tocilizumab (8%).

Infusion Reactions

In PJIA patients, infusion-related reactions are defined as all events occurring during or within 24 hours of an infusion. In the tocilizumab-IV all exposure population, 11 patients (6%) experienced an event during the infusion, and 38 patients (20.2%) experienced an event within 24 hours of an infusion. The most common events occurring during infusion were headache, nausea and hypotension, and occurring within 24 hours of infusion were dizziness and hypotension. In general, the adverse drug reactions observed during or within 24 hours of an infusion were similar in nature to those seen in RA and SJIA patients.

Immunogenicity

One patient, in the 10 mg/kg less than 30 kg group, developed positive anti-tocilizumab antibodies without developing a hypersensitivity reaction and subsequently withdrew from the study.

Systemic Juvenile Idiopathic Arthritis

The data described below reflect exposure to tocilizumab-IV in one randomized, double-blind, placebo-controlled trial of 112 pediatric patients with SJIA 2 to 17 years of age who had an inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids due to toxicity or lack of efficacy. At baseline, approximately half of the patients were taking 0.3 mg/kg/day corticosteroids or more, and almost 70% were taking methotrexate. The trial included a 12 week controlled phase followed by an open-label extension. In the 12 week double-blind, controlled portion of the clinical study, 75 patients received treatment with tocilizumab-IV (8 or 12 mg per kg based upon body weight). After 12 weeks or at the time of escape, due to disease worsening, patients were treated with tocilizumab-IV in the open-label extension phase.

The most common adverse events (at least 5%) seen in tocilizumab-IV treated patients in the 12 week controlled portion of the study were: upper respiratory tract infection, headache, nasopharyngitis and diarrhea.

Infections

In the 12 week controlled phase, the rate of all infections in the tocilizumab-IV group was 345 per 100 patient-years and 287 per 100 patient-years in the placebo group. In the open label extension over an average duration of 73 weeks of treatment, the overall rate of infections was 304 per 100 patient-years.

In the 12 week controlled phase, the rate of serious infections in the tocilizumab-IV group was 11.5 per 100 patient years. In the open label extension over an average duration of 73 weeks of treatment, the overall rate of serious infections was 11.4 per 100 patient years. The most commonly reported serious infections included pneumonia, gastroenteritis, varicella, and otitis media.

Macrophage Activation Syndrome

In the 12 week controlled study, no patient in any treatment group experienced macrophage activation syndrome (MAS) while on assigned treatment; 3 per 112 (3%) developed MAS during open-label treatment with tocilizumab-IV. One patient in the placebo group escaped to tocilizumab-IV 12 mg per kg at Week 2 due to severe disease activity, and ultimately developed MAS at Day 70. Two additional patients developed MAS during the long-term extension. All 3 patients had tocilizumab-IV dose interrupted (2 patients) or discontinued (1 patient) for the MAS event, received treatment, and the MAS resolved without sequelae. Based on a limited number of cases, the incidence of MAS does not appear to be elevated in the tocilizumab-IV SJIA clinical development experience; however no definitive conclusions can be made.

Infusion Reactions

Patients were not premedicated, however most patients were on concomitant corticosteroids as part of their background treatment for SJIA. Infusion related reactions were defined as all events occurring during or within 24 hours after an infusion. In the 12 week controlled phase, 4% of tocilizumab-IV and 0% of placebo treated patients experienced events occurring during infusion. One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment.

Within 24 hours after infusion, 16% of patients in the tocilizumab-IV treatment group and 5% of patients in the placebo group experienced an event. In the tocilizumab-IV group the events included rash, urticaria, diarrhea, epigastric discomfort, arthralgia and headache. One of these events, urticaria, was considered serious.

Anaphylaxis

Anaphylaxis was reported in 1 out of 112 patients (less than 1%) treated with tocilizumab-IV during the controlled and open label extension study.


DRUG INTERACTIONS

Interactions with CYP450 Substrates

Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with tocilizumab products may restore CYP450 activities to higher levels than those in the absence of tocilizumab products leading to increased metabolism of drugs that are CYP450 substrates. Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

Live Vaccines

Avoid use of live vaccines concurrently with TOFIDENCE.


USE IN PREGNANCY AND LACTATION

Based on animal data, there may be a potential risk to the fetus.

The limited available data with tocilizumab products in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects and miscarriage.

Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to TOFIDENCE in utero.

The lack of clinical data during lactation precludes clear determination of the risk of tocilizumab products to an infant during lactation.

Please see full Prescribing Information, including Boxed Warning.

© 2024 Biogen. All rights reserved. 05/24 TOF-US-0018

This site is intended for residents 18 years or older of the United States, Puerto Rico, and US territories. Actemra is a trademark of Genentech, lnc.
All other trademarks are the property of their respective owners.